Global Vaccine Conjugate Market Growth 2025-2031

February 2025 | 123 pages | ID: GCEFBE76C425EN
LP Information

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Vaccine Conjugate Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Vaccine Conjugate by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Vaccine Conjugate by Country/Region, 2020, 2024 & 2031
2.2 Vaccine Conjugate Segment by Type
  2.2.1 Hib Vaccine
  2.2.2 Meningococcal Vaccine
  2.2.3 Pneumococcal Vaccine
  2.2.4 Others
2.3 Vaccine Conjugate Sales by Type
  2.3.1 Global Vaccine Conjugate Sales Market Share by Type (2020-2025)
  2.3.2 Global Vaccine Conjugate Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Vaccine Conjugate Sale Price by Type (2020-2025)
2.4 Vaccine Conjugate Segment by Application
  2.4.1 Children
  2.4.2 Adult
2.5 Vaccine Conjugate Sales by Application
  2.5.1 Global Vaccine Conjugate Sale Market Share by Application (2020-2025)
  2.5.2 Global Vaccine Conjugate Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Vaccine Conjugate Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Vaccine Conjugate Breakdown Data by Company
  3.1.1 Global Vaccine Conjugate Annual Sales by Company (2020-2025)
  3.1.2 Global Vaccine Conjugate Sales Market Share by Company (2020-2025)
3.2 Global Vaccine Conjugate Annual Revenue by Company (2020-2025)
  3.2.1 Global Vaccine Conjugate Revenue by Company (2020-2025)
  3.2.2 Global Vaccine Conjugate Revenue Market Share by Company (2020-2025)
3.3 Global Vaccine Conjugate Sale Price by Company
3.4 Key Manufacturers Vaccine Conjugate Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Vaccine Conjugate Product Location Distribution
  3.4.2 Players Vaccine Conjugate Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR VACCINE CONJUGATE BY GEOGRAPHIC REGION

4.1 World Historic Vaccine Conjugate Market Size by Geographic Region (2020-2025)
  4.1.1 Global Vaccine Conjugate Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Vaccine Conjugate Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Vaccine Conjugate Market Size by Country/Region (2020-2025)
  4.2.1 Global Vaccine Conjugate Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Vaccine Conjugate Annual Revenue by Country/Region (2020-2025)
4.3 Americas Vaccine Conjugate Sales Growth
4.4 APAC Vaccine Conjugate Sales Growth
4.5 Europe Vaccine Conjugate Sales Growth
4.6 Middle East & Africa Vaccine Conjugate Sales Growth

5 AMERICAS

5.1 Americas Vaccine Conjugate Sales by Country
  5.1.1 Americas Vaccine Conjugate Sales by Country (2020-2025)
  5.1.2 Americas Vaccine Conjugate Revenue by Country (2020-2025)
5.2 Americas Vaccine Conjugate Sales by Type (2020-2025)
5.3 Americas Vaccine Conjugate Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Vaccine Conjugate Sales by Region
  6.1.1 APAC Vaccine Conjugate Sales by Region (2020-2025)
  6.1.2 APAC Vaccine Conjugate Revenue by Region (2020-2025)
6.2 APAC Vaccine Conjugate Sales by Type (2020-2025)
6.3 APAC Vaccine Conjugate Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Vaccine Conjugate by Country
  7.1.1 Europe Vaccine Conjugate Sales by Country (2020-2025)
  7.1.2 Europe Vaccine Conjugate Revenue by Country (2020-2025)
7.2 Europe Vaccine Conjugate Sales by Type (2020-2025)
7.3 Europe Vaccine Conjugate Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Vaccine Conjugate by Country
  8.1.1 Middle East & Africa Vaccine Conjugate Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Vaccine Conjugate Revenue by Country (2020-2025)
8.2 Middle East & Africa Vaccine Conjugate Sales by Type (2020-2025)
8.3 Middle East & Africa Vaccine Conjugate Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaccine Conjugate
10.3 Manufacturing Process Analysis of Vaccine Conjugate
10.4 Industry Chain Structure of Vaccine Conjugate

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Vaccine Conjugate Distributors
11.3 Vaccine Conjugate Customer

12 WORLD FORECAST REVIEW FOR VACCINE CONJUGATE BY GEOGRAPHIC REGION

12.1 Global Vaccine Conjugate Market Size Forecast by Region
  12.1.1 Global Vaccine Conjugate Forecast by Region (2026-2031)
  12.1.2 Global Vaccine Conjugate Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Vaccine Conjugate Forecast by Type (2026-2031)
12.7 Global Vaccine Conjugate Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Pfizer
  13.1.1 Pfizer Company Information
  13.1.2 Pfizer Vaccine Conjugate Product Portfolios and Specifications
  13.1.3 Pfizer Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Pfizer Main Business Overview
  13.1.5 Pfizer Latest Developments
13.2 GSK
  13.2.1 GSK Company Information
  13.2.2 GSK Vaccine Conjugate Product Portfolios and Specifications
  13.2.3 GSK Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 GSK Main Business Overview
  13.2.5 GSK Latest Developments
13.3 Sanofi
  13.3.1 Sanofi Company Information
  13.3.2 Sanofi Vaccine Conjugate Product Portfolios and Specifications
  13.3.3 Sanofi Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Sanofi Main Business Overview
  13.3.5 Sanofi Latest Developments
13.4 Merck
  13.4.1 Merck Company Information
  13.4.2 Merck Vaccine Conjugate Product Portfolios and Specifications
  13.4.3 Merck Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Merck Main Business Overview
  13.4.5 Merck Latest Developments
13.5 Walvax Biotechnology
  13.5.1 Walvax Biotechnology Company Information
  13.5.2 Walvax Biotechnology Vaccine Conjugate Product Portfolios and Specifications
  13.5.3 Walvax Biotechnology Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Walvax Biotechnology Main Business Overview
  13.5.5 Walvax Biotechnology Latest Developments
13.6 Royal (Wuxi) Bio-Pharmaceutical
  13.6.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  13.6.2 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolios and Specifications
  13.6.3 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Royal (Wuxi) Bio-Pharmaceutical Main Business Overview
  13.6.5 Royal (Wuxi) Bio-Pharmaceutical Latest Developments
13.7 Bharat Biotech
  13.7.1 Bharat Biotech Company Information
  13.7.2 Bharat Biotech Vaccine Conjugate Product Portfolios and Specifications
  13.7.3 Bharat Biotech Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Bharat Biotech Main Business Overview
  13.7.5 Bharat Biotech Latest Developments
13.8 Zhifei Biologic
  13.8.1 Zhifei Biologic Company Information
  13.8.2 Zhifei Biologic Vaccine Conjugate Product Portfolios and Specifications
  13.8.3 Zhifei Biologic Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Zhifei Biologic Main Business Overview
  13.8.5 Zhifei Biologic Latest Developments
13.9 Chengdu Olymvax Biopharmaceuticals
  13.9.1 Chengdu Olymvax Biopharmaceuticals Company Information
  13.9.2 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolios and Specifications
  13.9.3 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2020-2025)
  13.9.4 Chengdu Olymvax Biopharmaceuticals Main Business Overview
  13.9.5 Chengdu Olymvax Biopharmaceuticals Latest Developments
13.10 Beijing Minhai Biotechnology
  13.10.1 Beijing Minhai Biotechnology Company Information
  13.10.2 Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolios and Specifications
  13.10.3 Beijing Minhai Biotechnology Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2020-2025)
  13.10.4 Beijing Minhai Biotechnology Main Business Overview
  13.10.5 Beijing Minhai Biotechnology Latest Developments
13.11 CanSinoBIO
  13.11.1 CanSinoBIO Company Information
  13.11.2 CanSinoBIO Vaccine Conjugate Product Portfolios and Specifications
  13.11.3 CanSinoBIO Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2020-2025)
  13.11.4 CanSinoBIO Main Business Overview
  13.11.5 CanSinoBIO Latest Developments
13.12 Beijing Xiangrui Biological Products
  13.12.1 Beijing Xiangrui Biological Products Company Information
  13.12.2 Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolios and Specifications
  13.12.3 Beijing Xiangrui Biological Products Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2020-2025)
  13.12.4 Beijing Xiangrui Biological Products Main Business Overview
  13.12.5 Beijing Xiangrui Biological Products Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Vaccine Conjugate Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Vaccine Conjugate Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Hib Vaccine
Table 4. Major Players of Meningococcal Vaccine
Table 5. Major Players of Pneumococcal Vaccine
Table 6. Major Players of Others
Table 7. Global Vaccine Conjugate Sales byType (2020-2025) & (K Doses)
Table 8. Global Vaccine Conjugate Sales Market Share byType (2020-2025)
Table 9. Global Vaccine Conjugate Revenue byType (2020-2025) & ($ million)
Table 10. Global Vaccine Conjugate Revenue Market Share byType (2020-2025)
Table 11. Global Vaccine Conjugate Sale Price byType (2020-2025) & (US$/Dose)
Table 12. Global Vaccine Conjugate Sale by Application (2020-2025) & (K Doses)
Table 13. Global Vaccine Conjugate Sale Market Share by Application (2020-2025)
Table 14. Global Vaccine Conjugate Revenue by Application (2020-2025) & ($ million)
Table 15. Global Vaccine Conjugate Revenue Market Share by Application (2020-2025)
Table 16. Global Vaccine Conjugate Sale Price by Application (2020-2025) & (US$/Dose)
Table 17. Global Vaccine Conjugate Sales by Company (2020-2025) & (K Doses)
Table 18. Global Vaccine Conjugate Sales Market Share by Company (2020-2025)
Table 19. Global Vaccine Conjugate Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Vaccine Conjugate Revenue Market Share by Company (2020-2025)
Table 21. Global Vaccine Conjugate Sale Price by Company (2020-2025) & (US$/Dose)
Table 22. Key Manufacturers Vaccine Conjugate Producing Area Distribution and Sales Area
Table 23. Players Vaccine Conjugate Products Offered
Table 24. Vaccine Conjugate Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Vaccine Conjugate Sales by Geographic Region (2020-2025) & (K Doses)
Table 28. Global Vaccine Conjugate Sales Market Share Geographic Region (2020-2025)
Table 29. Global Vaccine Conjugate Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Vaccine Conjugate Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Vaccine Conjugate Sales by Country/Region (2020-2025) & (K Doses)
Table 32. Global Vaccine Conjugate Sales Market Share by Country/Region (2020-2025)
Table 33. Global Vaccine Conjugate Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Vaccine Conjugate Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Vaccine Conjugate Sales by Country (2020-2025) & (K Doses)
Table 36. Americas Vaccine Conjugate Sales Market Share by Country (2020-2025)
Table 37. Americas Vaccine Conjugate Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Vaccine Conjugate Sales byType (2020-2025) & (K Doses)
Table 39. Americas Vaccine Conjugate Sales by Application (2020-2025) & (K Doses)
Table 40. APAC Vaccine Conjugate Sales by Region (2020-2025) & (K Doses)
Table 41. APAC Vaccine Conjugate Sales Market Share by Region (2020-2025)
Table 42. APAC Vaccine Conjugate Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Vaccine Conjugate Sales byType (2020-2025) & (K Doses)
Table 44. APAC Vaccine Conjugate Sales by Application (2020-2025) & (K Doses)
Table 45. Europe Vaccine Conjugate Sales by Country (2020-2025) & (K Doses)
Table 46. Europe Vaccine Conjugate Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Vaccine Conjugate Sales byType (2020-2025) & (K Doses)
Table 48. Europe Vaccine Conjugate Sales by Application (2020-2025) & (K Doses)
Table 49. Middle East & Africa Vaccine Conjugate Sales by Country (2020-2025) & (K Doses)
Table 50. Middle East & Africa Vaccine Conjugate Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Vaccine Conjugate Sales byType (2020-2025) & (K Doses)
Table 52. Middle East & Africa Vaccine Conjugate Sales by Application (2020-2025) & (K Doses)
Table 53. Key Market Drivers & Growth Opportunities of Vaccine Conjugate
Table 54. Key Market Challenges & Risks of Vaccine Conjugate
Table 55. Key IndustryTrends of Vaccine Conjugate
Table 56. Vaccine Conjugate Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Vaccine Conjugate Distributors List
Table 59. Vaccine Conjugate Customer List
Table 60. Global Vaccine Conjugate SalesForecast by Region (2026-2031) & (K Doses)
Table 61. Global Vaccine Conjugate RevenueForecast by Region (2026-2031) & ($ millions)
Table 62. Americas Vaccine Conjugate SalesForecast by Country (2026-2031) & (K Doses)
Table 63. Americas Vaccine Conjugate Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 64. APAC Vaccine Conjugate SalesForecast by Region (2026-2031) & (K Doses)
Table 65. APAC Vaccine Conjugate Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Europe Vaccine Conjugate SalesForecast by Country (2026-2031) & (K Doses)
Table 67. Europe Vaccine Conjugate RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa Vaccine Conjugate SalesForecast by Country (2026-2031) & (K Doses)
Table 69. Middle East & Africa Vaccine Conjugate RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Global Vaccine Conjugate SalesForecast byType (2026-2031) & (K Doses)
Table 71. Global Vaccine Conjugate RevenueForecast byType (2026-2031) & ($ millions)
Table 72. Global Vaccine Conjugate SalesForecast by Application (2026-2031) & (K Doses)
Table 73. Global Vaccine Conjugate RevenueForecast by Application (2026-2031) & ($ millions)
Table 74. Pfizer Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 75. Pfizer Vaccine Conjugate Product Portfolios and Specifications
Table 76. Pfizer Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 77. Pfizer Main Business
Table 78. Pfizer Latest Developments
Table 79. GSK Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 80. GSK Vaccine Conjugate Product Portfolios and Specifications
Table 81. GSK Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 82. GSK Main Business
Table 83. GSK Latest Developments
Table 84. Sanofi Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 85. Sanofi Vaccine Conjugate Product Portfolios and Specifications
Table 86. Sanofi Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 87. Sanofi Main Business
Table 88. Sanofi Latest Developments
Table 89. Merck Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 90. Merck Vaccine Conjugate Product Portfolios and Specifications
Table 91. Merck Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 92. Merck Main Business
Table 93. Merck Latest Developments
Table 94. Walvax Biotechnology Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 95. Walvax Biotechnology Vaccine Conjugate Product Portfolios and Specifications
Table 96. Walvax Biotechnology Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 97. Walvax Biotechnology Main Business
Table 98. Walvax Biotechnology Latest Developments
Table 99. Royal (Wuxi) Bio-Pharmaceutical Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 100. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolios and Specifications
Table 101. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 102. Royal (Wuxi) Bio-Pharmaceutical Main Business
Table 103. Royal (Wuxi) Bio-Pharmaceutical Latest Developments
Table 104. Bharat Biotech Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 105. Bharat Biotech Vaccine Conjugate Product Portfolios and Specifications
Table 106. Bharat Biotech Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 107. Bharat Biotech Main Business
Table 108. Bharat Biotech Latest Developments
Table 109. Zhifei Biologic Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 110. Zhifei Biologic Vaccine Conjugate Product Portfolios and Specifications
Table 111. Zhifei Biologic Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 112. Zhifei Biologic Main Business
Table 113. Zhifei Biologic Latest Developments
Table 114. Chengdu Olymvax Biopharmaceuticals Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 115. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolios and Specifications
Table 116. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 117. Chengdu Olymvax Biopharmaceuticals Main Business
Table 118. Chengdu Olymvax Biopharmaceuticals Latest Developments
Table 119. Beijing Minhai Biotechnology Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 120. Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolios and Specifications
Table 121. Beijing Minhai Biotechnology Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 122. Beijing Minhai Biotechnology Main Business
Table 123. Beijing Minhai Biotechnology Latest Developments
Table 124. CanSinoBIO Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 125. CanSinoBIO Vaccine Conjugate Product Portfolios and Specifications
Table 126. CanSinoBIO Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 127. CanSinoBIO Main Business
Table 128. CanSinoBIO Latest Developments
Table 129. Beijing Xiangrui Biological Products Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 130. Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolios and Specifications
Table 131. Beijing Xiangrui Biological Products Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 132. Beijing Xiangrui Biological Products Main Business
Table 133. Beijing Xiangrui Biological Products Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Vaccine Conjugate
Figure 2. Vaccine Conjugate Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaccine Conjugate Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Vaccine Conjugate Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Vaccine Conjugate Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Vaccine Conjugate Sales Market Share by Country/Region (2024)
Figure 10. Vaccine Conjugate Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Hib Vaccine
Figure 12. Product Picture of Meningococcal Vaccine
Figure 13. Product Picture of Pneumococcal Vaccine
Figure 14. Product Picture of Others
Figure 15. Global Vaccine Conjugate Sales Market Share byType in 2025
Figure 16. Global Vaccine Conjugate Revenue Market Share byType (2020-2025)
Figure 17. Vaccine Conjugate Consumed in Children
Figure 18. Global Vaccine Conjugate Market: Children (2020-2025) & (K Doses)
Figure 19. Vaccine Conjugate Consumed in Adult
Figure 20. Global Vaccine Conjugate Market: Adult (2020-2025) & (K Doses)
Figure 21. Global Vaccine Conjugate Sale Market Share by Application (2024)
Figure 22. Global Vaccine Conjugate Revenue Market Share by Application in 2025
Figure 23. Vaccine Conjugate Sales by Company in 2025 (K Doses)
Figure 24. Global Vaccine Conjugate Sales Market Share by Company in 2025
Figure 25. Vaccine Conjugate Revenue by Company in 2025 ($ millions)
Figure 26. Global Vaccine Conjugate Revenue Market Share by Company in 2025
Figure 27. Global Vaccine Conjugate Sales Market Share by Geographic Region (2020-2025)
Figure 28. Global Vaccine Conjugate Revenue Market Share by Geographic Region in 2025
Figure 29. Americas Vaccine Conjugate Sales 2020-2025 (K Doses)
Figure 30. Americas Vaccine Conjugate Revenue 2020-2025 ($ millions)
Figure 31. APAC Vaccine Conjugate Sales 2020-2025 (K Doses)
Figure 32. APAC Vaccine Conjugate Revenue 2020-2025 ($ millions)
Figure 33. Europe Vaccine Conjugate Sales 2020-2025 (K Doses)
Figure 34. Europe Vaccine Conjugate Revenue 2020-2025 ($ millions)
Figure 35. Middle East & Africa Vaccine Conjugate Sales 2020-2025 (K Doses)
Figure 36. Middle East & Africa Vaccine Conjugate Revenue 2020-2025 ($ millions)
Figure 37. Americas Vaccine Conjugate Sales Market Share by Country in 2025
Figure 38. Americas Vaccine Conjugate Revenue Market Share by Country (2020-2025)
Figure 39. Americas Vaccine Conjugate Sales Market Share byType (2020-2025)
Figure 40. Americas Vaccine Conjugate Sales Market Share by Application (2020-2025)
Figure 41. United States Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 42. Canada Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 43. Mexico Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 44. Brazil Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 45. APAC Vaccine Conjugate Sales Market Share by Region in 2025
Figure 46. APAC Vaccine Conjugate Revenue Market Share by Region (2020-2025)
Figure 47. APAC Vaccine Conjugate Sales Market Share byType (2020-2025)
Figure 48. APAC Vaccine Conjugate Sales Market Share by Application (2020-2025)
Figure 49. China Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 50. Japan Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 51. South Korea Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 52. Southeast Asia Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 53. India Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 54. Australia Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 55. ChinaTaiwan Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 56. Europe Vaccine Conjugate Sales Market Share by Country in 2025
Figure 57. Europe Vaccine Conjugate Revenue Market Share by Country (2020-2025)
Figure 58. Europe Vaccine Conjugate Sales Market Share byType (2020-2025)
Figure 59. Europe Vaccine Conjugate Sales Market Share by Application (2020-2025)
Figure 60. Germany Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 61.France Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 62. UK Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 63. Italy Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 64. Russia Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 65. Middle East & Africa Vaccine Conjugate Sales Market Share by Country (2020-2025)
Figure 66. Middle East & Africa Vaccine Conjugate Sales Market Share byType (2020-2025)
Figure 67. Middle East & Africa Vaccine Conjugate Sales Market Share by Application (2020-2025)
Figure 68. Egypt Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 69. South Africa Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 70. Israel Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 71.Turkey Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 72. GCC Countries Vaccine Conjugate Revenue Growth 2020-2025 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Vaccine Conjugate in 2025
Figure 74. Manufacturing Process Analysis of Vaccine Conjugate
Figure 75. Industry Chain Structure of Vaccine Conjugate
Figure 76. Channels of Distribution
Figure 77. Global Vaccine Conjugate Sales MarketForecast by Region (2026-2031)
Figure 78. Global Vaccine Conjugate Revenue Market ShareForecast by Region (2026-2031)
Figure 79. Global Vaccine Conjugate Sales Market ShareForecast byType (2026-2031)
Figure 80. Global Vaccine Conjugate Revenue Market ShareForecast byType (2026-2031)
Figure 81. Global Vaccine Conjugate Sales Market ShareForecast by Application (2026-2031)
Figure 82. Global Vaccine Conjugate Revenue Market ShareForecast by Application (2026-2031)